Arthritis Research & Therapy

Table 3 Pretreatment (baseline) and posttreatment chemokine levels in responders and nonresponders. P values were determined by analysis of variance (ANOVA) for repeated measures

From: Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study

	Responders		Nonresponders
	mean ± SD	p value	mean ± SD	p value
CXCL10 (pg/ml)
Pretreatment	605.5 ± 580.6	0.01*	283.2 ± 265.1	0.04*
Posttreatment	411.1 ± 458.3	0.01*	218.4 ± 237.3	0.04*
CXCL13 (pg/ml)
Pretreatment	382.7 ± 644.3	<0.0001*	26.7 ± 23.8	0.86
Posttreatment	90.6 ± 128.2	<0.0001*	35.7 ± 46.8	0.86
CCL20 (pg/ml)
Pretreatment	13.6 ± 12.7	0.003*	19.0 ± 31.0	0.047*
Posttreatment	6.9 ± 8.9	0.003*	7.2 ± 7.2	0.047*

CXCL10 C-X-C motif chemokine 10, CXCL13 C-X-C motif chemokine 13, CCL20 C-C motif chemokine 20
*p < 0.05

Back to article page

ISSN: 1478-6362

Contact us

General enquiries: journalsubmissions@springernature.com